Table 2.
Tumor size according to patient presentation
| Patient presentation | Tumor size on MRI (mm) | P value | Tumor size on MRI (mm) | P value | ||||
|---|---|---|---|---|---|---|---|---|
| [Mass + non-mass] | [Mass only] | |||||||
| Median | Range | 0.002* | Median | Range | 0.001* | |||
| Self-detecteda | (n = 40) | 28 | (11–82) | (n = 39) | 28 | (16–82) | ||
| Detected on MMG or US | ||||||||
| Detected by routine-screening examsb | (n = 15) | 21 | (9–110) | (n = 12) | 23 | (9–110) | ||
| Detected by post-operative contralateral follow-up | (n = 2) | 17.5 | (13–22) | (n = 2) | 17.5 | (13–22) | ||
| Detected on MRI | ||||||||
| Detected by post-operative contralateral follow-up | (n = 2) | 4 | (3–5) | (n = 2) | 4 | (3–5) | ||
| Detected by HBOC surveillance exam | (n = 1) | 7 | (n = 1) | 7 | ||||
| Detected on other than MRI for some purposesc | (n = 3) | 19 | (17–57) | (n = 2) | 18 | (17–19) | ||
| Undetectable on MRId | (n = 4) | 0 | ||||||
| Unknown | (n = 5) | |||||||
MMG mammography, US ultrasonography, HBOC hereditary breast and ovarian cancer
*Statistically significant
aPatients who presented with clinical symptoms (i.e., mass, pain, or nipple discharge); these patients had no prior routine-screening exams, or symptoms occurred between interval screening exams
bPublicly available routine cancer screening in Japan
cThese included two cases for pre-operative contralateral evaluation and one case detected on chest CT incidentally
dTwo patients underwent MRI after US-guided vacuum-assisted breast biopsies, and two breast cancers were diagnosed by CRRM (contralateral risk-reducing mastectomy)